Drug Development for Central Nervous System Diseases Using In Vitro Blood-brain Barrier Models and Drug Repositioning.

Drug Development for Central Nervous System Diseases Using In Vitro Blood-brain Barrier Models and Drug Repositioning. Curr Pharm Des. 2020 Feb 23;: Authors: Morofuji Y, Nakagawa S Abstract An important goal of biomedical research is to translate basic research findings into practical clinical implementation. Despite the advances in the technology used in drug discovery, the development of drugs for central nervous system diseases remains challenging. The failure rate for new drugs targeting important central nervous system diseases is high compared to most other areas of drug discovery. The main reason of the failure is the poor penetration efficacy across the blood-brain barrier. The blood-brain barrier represents the bottleneck in central nervous system drug development and is the most important factor limiting the future growth of neurotherapeutics. Meanwhile, drug repositioning has been becoming increasing popular and it seems a promising field in central nervous system drug development. In vitro blood-brain barrier models with high predictability are expected for drug development and drug repositioning. In this review, we discuss the recent progress of in vitro BBB models and the drug repositioning for central nervous system diseases. PMID: 32091330 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research